GSK and Servier to increase production of anti-HIV drug in Russia
UK pharma major GlaxoSmithKline (LSE: GSK) and privately-held French peer Servier have reached an agreement for increase the production of dolutegravir, which is a drug for the treatment of HIV at the facilities of Servier RUS plant in Moscow, according to recent statements by the press service of the Department of Investment and Industrial Policy of the Moscow city government.
According to the press service, a project for contract manufacturing of an innovative drug used for the first and second lines of HIV therapy from GSK and its majority-owned ViiV Healthcare was launched at the Servier RUS Moscow plant in 2016.
Full cycle production began in 2019. During this time, the company has manufactured and shipped more than 2 million packages of the drug. The latest agreement will also allow to expand the portfolio of locally produced innovative antiretroviral drugs at the enterprise.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze